Dateline City:
KENILWORTH, N.J.
Additional Real-World Analyses from DYSIS and DYSIS II Assessing the Treatment of Dyslipidemia to be Presented
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that new analyses from the investigational IMPROVE-IT
(IMProved Reduction of Outcomes: VYTORIN Efficacy International Trial)
study of VYTORIN (ezetimibe and simvastatin), the TECOS
(Trial Evaluating Cardiovascular Outcomes with Sitagliptin)
cardiovascular safety trial of JANUVIA (sitagliptin), and
real-world data from the Dyslipidemia International Study (DYSIS I and
DYSIS II) will be presented at the upcoming European Socie
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-391-0131orInvestor:Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more